http://www.xconomy.com/seattle/2009/01/28/zymogenetics-takes-back-full-rights-to-cancer-drug-candidate/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/seattle/2009/01/28/zymogenetics-takes-back-full-rights-to-cancer-drug-candidate/comment-page-1/#comment-240532 Zymo Genetics IL-21 shrinks malignant melanoma | Pharma Strategy Blog Tue, 26 Oct 2010 21:20:09 +0000 http://www.xconomy.com/?p=10409#comment-240532 [...] ZymoGenetics Takes Back Full Rights to Cancer Drug Candidate (xconomy.com) This entry was posted in Immunology, Mechanism of Action, New products, Pipeline, Renal Cancer, Targeted Therapies and tagged commercial landscape opprtunity assessments, competitive intelligence, KOL market research, oncology hematology, pharmaceutical biotechnology marketing strategy consulting, social media monitoring. Bookmark the permalink. ← Twitter is a great source for Pharma news alerts: Update on Rezonic links for 2009-05-14 → blog comments powered by Disqus /* */ /* */ /* */ [...] [...] ZymoGenetics Takes Back Full Rights to Cancer Drug Candidate (xconomy.com) This entry was posted in Immunology, Mechanism of Action, New products, Pipeline, Renal Cancer, Targeted Therapies and tagged commercial landscape opprtunity assessments, competitive intelligence, KOL market research, oncology hematology, pharmaceutical biotechnology marketing strategy consulting, social media monitoring. Bookmark the permalink. ← Twitter is a great source for Pharma news alerts: Update on Rezonic links for 2009-05-14 → blog comments powered by Disqus /* */ /* */ /* */ [...]

]]>